Edition:
United Kingdom

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

3.67USD
13 Nov 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$3.67
Open
$3.97
Day's High
$4.00
Day's Low
$3.58
Volume
210,342
Avg. Vol
412,182
52-wk High
$7.21
52-wk Low
$1.22

Latest Key Developments (Source: Significant Developments)

Arqule Announces Pricing Of $60.5 Mln Public Offering Of Common Stock
Wednesday, 11 Jul 2018 

July 11 (Reuters) - ArQule Inc ::ARQULE ANNOUNCES PRICING OF $60.5 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.0 MILLION COMMON SHARES PRICED AT $5.50PER SHARE.  Full Article

Arqule Files Prospectus Related To Seconday Offering Of Up To 10.6 Mln Shares
Thursday, 17 May 2018 

May 17 (Reuters) - ArQule Inc ::ARQULE INC FILES PROSPECTUS RELATED TO OFFERING UP TO 10.6 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Arqule Reports Q1 Loss Per Share Of $0.07
Monday, 7 May 2018 

May 7 (Reuters) - ArQule Inc ::ARQULE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.07.SEES FY 2018 REVENUE $14 MILLION TO $17 MILLION.Q1 REVENUE $4.138 MILLION.Q1 REVENUE VIEW $2.1 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 LOSS PER SHARE $0.18 TO $0.24.ARQULE EXPECTS TO END 2018 WITH BETWEEN $40 AND $42 MILLION IN CASH AND MARKETABLE SECURITIES.  Full Article

Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib
Tuesday, 17 Apr 2018 

April 17 (Reuters) - ArQule Inc ::ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA.ARQULE INC - UNDER TERMS OF AGREEMENT, ARQULE WILL RECEIVE AN UPFRONT PAYMENT OF $10 MILLION.ARQULE INC - ARQULE ELIGIBLE TO RECEIVE UP TO $336 MILLION INCLUDING UPFRONT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.ARQULE - UNDER CERTAIN CIRCUMSTANCES, CO MAY HAVE OPPORTUNITY TO PROMOTE DERAZANTINIB IN U.S. DIRECTLY.ARQULE - ALSO ENTITLED TO RECEIVE STAGGERED SINGLE-DIGIT TO DOUBLE-DIGIT ROYALTIES ON NET SALES UPON COMMERCIALIZATION.ARQULE - BASILEA WILL BE RESPONSIBLE FOR ALL COSTS AND EXPENSES OF DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION IN ITS TERRITORY.  Full Article

ArQule Files For Offering Of Up To 17.1 Million Shares
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Arqule Inc ::ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Arqule reports Q3 loss per share $0.09
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Arqule Inc :Arqule reports third quarter 2017 financial results.Q3 loss per share $0.09.Sees FY 2017 loss per share $0.38 to $0.40.Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Arqule Inc - ‍Expects to end 2017 with between $47 and $49 million in cash and marketable securities​.Arqule Inc - ‍For 2017, Arqule expects net use of cash to range between $25 and $27 million​.  Full Article

ArQule announces $9.5 mln private placement of preferred stock
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - ArQule Inc :ArQule announces $9.5 million private placement of preferred stock.ArQule Inc - to use proceeds to advance clinical trials related to proprietary pipeline, including derazantinib, miransertib, ARQ 531 & ARQ 751​.  Full Article

Arqule announces $15.7 mln private placement of common stock
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Arqule Inc :Arqule announces $15.7 million private placement of common stock.Arqule Inc - ‍intends to use net proceeds from offering to advance clinical trials related to its proprietary pipeline​.Arqule Inc - expects in first part of 2019 to obtain arq 531 PK/PD data from phase 1a trial in patients with refractory b-cell malignancies.Arqule inc - ‍company currently anticipates cash and marketable securities to provide funding into 2019​.Arqule Inc - ‍expects to end 2017 with between $38 and $40 million in cash and marketable securities​.Arqule Inc - expects in first part of 2019 to initiate phase 1b proof of concept trial​ for arq 531.Arqule-Expects in first part of 2019 to present authorities with proof of concept data to initiate registrational trial in proteus syndrome​ for ARQ 092.  Full Article